Evidence map›Paper›PMID 38546689›Full record

Trial reportHaematologica2024

Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.

Elisa Jacobsen Pulczynski, Mikkel Runason Simonsen, Outi Kuittinen, Unn-Merete Fagerli, Martin Erlanson, Øystein Fluge, Sirpa Leppä, Bjørn Østenstad, Alexander Fosså, Mikael Eriksson and 6 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 4 countries.

Elisa Jacobsen PulczynskiDepartment of Haematology, Aarhus University Hospital, Aarhus, Denmark; Department of Haematology, Region Hospital Goedstrup, Herning.
Mikkel Runason SimonsenDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Mathematical Sciences, Aalborg University, Aalborg.
Outi KuittinenDepartment of Oncology, Kuopio University Hospital Cancer Center, Kuopio, Finland; Faculty of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio.
Unn-Merete FagerliDepartment of Oncology, St Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of science and technology (NTNU), Trondheim, Norway.
Martin ErlansonDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.
Øystein FlugeDepartment of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
Sirpa LeppäResearch Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
Bjørn ØstenstadDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Alexander FossåDepartment of Oncology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway.
Mikael ErikssonDepartment of Oncology, Skane University Hospital, Lund, Sweden; Medical Oncology, Lund University, Lund, Sweden.
Tarec El-GalalyDepartment of Hematology, Aalborg University Hospital, Aalborg.
Hanne KuitunenCancer Centre, Oulu University Hospital, Oulu.
Karin PapworthDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.
Maria LjungqvistDepartment of Clinical Science and Education, Södersjukhuste, Karolinska Insitutet, Stockholm, Sweden; Haematology Centre, Karolinska University Hospital, Stockholm, Sweden.
Martin B PedersenDepartment of Haematology, Aarhus University Hospital, Aarhus.
Marjukka PollariResearch Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere. marjukka.pollari@pirha.fi.
Aalborg University Hospital · DKUmeå University · SEAarhus University Hospital · DKHaukeland University Hospital · NOHelsinki University Hospital · FIKarolinska University Hospital · SEKuopio University Hospital · FINorwegian University of Science and Technology · NOOslo University Hospital · NOOulu University Hospital · FIRegionshospitalet Herning · DKSkåne University Hospital · SETampere University · FIUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Central Nervous System NeoplasmsTemozolomideAgedAged, 80 and overAntineoplastic Agents, AlkylatingCancer SurvivorsDacarbazineFemaleFollow-Up StudiesHumansLymphomaMaintenance ChemotherapyMaleMiddle AgedTreatment OutcomeAntineoplastic Agents, AlkylatingDacarbazineTemozolomide

Identifiers

PMID38546689
PMCPMC11215357
OpenAlexW4393264196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.